13th Charles Rodolphe Brupbacher Symposium in conjunction with the

Charles Rodolphe Brupbacher Prize for Cancer Research 2017



February 1 - 3, 2017

Breakthroughs in Cancer Research and Therapy



Symposium Location:

ETH Swiss Federal Institute of Technology, Main Building, Rämistrasse 101, AudiMax (HG F 30)

Tuesday, January 31, 2017

19:00 – 20:00 Charles Rodolphe Brupbacher Public Lecture

Reinhard Dummer: Ist Hautkrebs heilbar? Universität Zürich Zentrum, Rämistr. 71, G 201 (Aula)

Dear Participant,

Welcome to the 13th Charles Rodolphe Brupbacher Symposium. During the coming two and a half days, you will hear talks covering the key topics of cutting-edge cancer research including cancer genomics, cancer signalling and targeted therapy, genomic instability, cancer epigenetics, cancer stem cells, tumour microenvironment and tumour immunity, and cancer therapy.

You will also have the opportunity to discuss the latest developments in cancer research with the authors of more than 200 posters during Wednesday evening's poster session.

On Thursday afternoon, three outstanding scientists who made seminal contributions to two of these important research topics will receive the highly-prestigious Charles Rodolphe Brupbacher Cancer Research Prize 2017.

We hope that you will enjoy the symposium and look forward to your active participation and stimulating discussions.

Josef Jiricny

Nancy Hynes

Nancy Heprer

Wednesday, February 1, 2017

12:00 – 13:30 Registration and Sandwich Lunch

13:30 – 15:00 Cancer Genomics

Chair: Holger Moch, Zurich

Richard Houlston: Polygenic susceptibility to colorectal cancer - mechanisms and impact Jussi Taipale: Systems biology of cancer Charles Swanton: Cancer chromosomal instability, diversity and evolution: TRACERx

15:00 – 15:30 Coffee break

15:30 – 17:30 <u>Cancer Signalling and Targeted Therapy</u> Chair: Nancy Hynes, Basel

Myles Brown: Hacking the hormone code in cancer

Yibin Kang: Stromal niches in bone that mediate the seeding, progression and treatment resistance of metastatic breast cancer

Lew Cantley: PI 3-kinase and cancer metabolism

Gerard Evan: RAS & MYC cooperation:

2017 update

18:30 – 21:30 Posters, Beer and Pretzels

Evening for all participants

Thursday, February 2, 2017

08:00-08:30 Registration and Coffee

08:30 – 10:00 Genomic Instability

Chair: Lauri Aaltonen, Helsinki

Simon Boulton: Mechanism and regulation of DNA-protein crosslink repair by the DNA-dependent metalloprotease SPRTN

David Pellman: Rapid evolution of the cancer

karyotype

Angelika Amon: Aneuploidy and cancer - a complicated relationship

10:00 – 10:30 Coffee break

10:30 – 12:00 Cancer Epigenetics

Chair: Josef Jiricny, Zurich

Adrian Bird: Genetic determinants of the epigenome in development and cancer

Maarten van Lohuizen: Context-dependent roles of polycomb repressors in cancer and development

Margaret Goodell: DNMT3A in hematopoietic stem cells, cancer and aging

12:00 – 13:30 Lunch and Coffee

13:30 – 15:00 Cancer Stem Cells

Chair: Markus G. Manz, Zurich

Kornelia Polyak: Heterogeneity in breast cancer **Benjamin Ebert**: Clinical and biological consequences of clonal hematopoiesis

Yusuf Hannun: Contributions of extrinsic factors

to cancer

15:00 – 15:30 Coffee break

15:30 – 17:00 Tumour Microenvironment,

Tumour Immunity

Chair: Alexander Markham, Leeds

Miriam Merad: Contribution of myeloid cells to

tumour outcome

Guido Kroemer: Cell death in pathophysiology:

inexorable, avoidable or desirable

Laurence Zitvogel: The unsuspected impact of

the gut microbiota on cancer immunosurveillance

17:15 – 18:45 **Award Ceremony**

Charles Rodolphe Brupbacher Prize for Cancer Research 2017

Public Event

19:00 - 19:30 Apéro

Friday, February 3, 2017

08:00 - 08:30 Coffee

08:30 – 10:00 <u>Breakthroughs in Cancer Therapy</u>

Chair: Miriam Merad, New York

Michael Hallek: Towards control of chronic

lymphocytic leukemia

Jedd Wolchok: Combination checkpoint blockade:

combinations and mechanisms

Mark O'Connor: Development of olaparib: the first cancer therapy based on a targeted

DNA damage response inhibitor

10:00 – 10:30 Coffee break

10:30 – 11:30 Breakthroughs in Cancer Biology

Chair: Markus G. Manz, Zurich

Alberto Bardelli: Cancer evolution as a

therapeutic target

David Lane: Drug discovery in the p53 pathway

11:30 – 12:00 **Young Investigator Awards**

Nancy Hynes and Josef Jiricny

Public Event

The selection will take place Wednesday evening (Posters, Beer and Pretzels), in the presence of the jury composed of the invited speakers and the Scientific Advisory Board. During the Symposium breaks the presenters are asked to be available for additional exchanges with the jury and with their colleagues.

12:15 End of Meeting

Poster abstract submission until: December 1, 2016

Registration until: January 30, 2017

CME Credits:

Kernfortbildungscredits AIM 12,5 points SGMO 12 points SGPath 12 points VSKT 3 points

Registration (free of charge) and poster abstract submission: www.brupbacher-foundation.org

Scientific Secretariat
Bahnhofstrasse 24

Charles Rodolphe Brupbacher Foundation Zollstrasse 2 P.O. Box 1611

P.O. Box 8024 Zurich Switzerland cher-foundation.org

9490 Vaduz Principality of Liechtenstein office@brupbacher-foundation.org www.brupbacher-foundation.org